Work Here?
Overview
Androlabs is a global pharmaceutical company focused on men’s health. It develops and sells testosterone replacement and erectile dysfunction medications, aiming to reduce the life expectancy gap between men and women. Beyond products, Androlabs builds an inclusive community for men, addressing knowledge gaps and overlooked health issues, and encourages openness about vulnerability. The company operates in over 20 countries in Europe and Australia and works with healthcare professionals to improve men’s health outcomes. It belongs to the same corporate group as Simple Pharma and seeks new partners who share a passion for men’s health. Its goal is to extend healthy, active lives for men by providing targeted therapies and support, while challenging stereotypes and facilitating better care for men across multiple markets.
About Androlabs
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2022
Get referred to Androlabs
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 France launch completed Testavan coverage across major European markets.
- August 2026 Switzerland partnership with EffRx broadens access and prescriber reach.
- Androlabs cites six million European patient uses, supporting brand credibility and refill economics.
What critics are saying
- Androlabs depends on two legacy products, leaving revenue exposed to generic competition.
- Simple Pharma’s Santander-backed portfolio supports Androlabs, creating group-level financing dependency.
- If Testavan uptake stalls in France, European expansion loses its main growth thesis.
What makes Androlabs unique
- Androlabs is the first global pharmaceutical company solely focused on men’s health.
- Testavan and Vitaros target hypogonadism and erectile dysfunction across Europe.
- Its 2026 France and Switzerland partnerships extend distribution through local specialists.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Paid Vacation
Remote Work Options
Flexible Work Hours
Commuter Benefits
Gym Membership
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 31%1 year growth
↑ 31%2 year growth
↑ 23%Androlabs expands French footprint with Testavan partnership. 27 July 2026 Men's health specialist Androlabs has expanded its European commercial presence through a partnership with Laboratoires Majorelle to market Testavan (testosterone) in France. The agreement makes the testosterone replacement therapy commercially available across Androlabs' main European markets, the company said, completing a regional rollout aimed at improving access to treatments for men's health conditions. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 24 April 2026 23 July 2026 22 July 2026 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 27 July 2026 Company spotlight. A Basel-headquartered global oncology company whose BTK inhibitor zanubrutinib has become the US market-share leader in its class, backed by 78-month CLL follow-up data and approvals across 80 markets. More features in pharmaceutical. 27 July 2026 25 July 2026
Androlabs is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Androlabs
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
London, United Kingdom
Founded
2022
Androlabs is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today